Investigating genetic factors that influence the risk of ALS
SARM1 functional polymorphisms and their contribution to ALS risk
This study is looking at how changes in a specific gene called SARM1 might affect the chances of developing ALS, helping us understand how it can either harm or protect nerve cells, which could lead to new ways to help people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10989918 on NIH RePORTER |
What this research studies
This research explores how specific genetic variations in the SARM1 gene may contribute to the risk of developing amyotrophic lateral sclerosis (ALS). By examining the role of SARM1 in axon degeneration, the study aims to understand how certain mutations can either promote or protect against neurodegeneration. The researchers will analyze the mechanisms by which SARM1 influences axon survival and cell death, potentially identifying genetic markers that could inform patient risk profiles. This work may lead to new insights into ALS pathology and therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a family history of ALS or those diagnosed with the condition who may have specific genetic variants.
Not a fit: Patients with ALS who do not have any genetic variations related to SARM1 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better understanding of ALS risk factors and the development of targeted therapies.
How similar studies have performed: Other research has shown promising results in understanding genetic contributions to neurodegenerative diseases, suggesting that this approach may yield valuable insights.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Bloom, Adam Joseph — Washington University
- Study coordinator: Bloom, Adam Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.